The price of medical drugs in Switzerland remains higher than in other major European markets, especially for generic drugs, which are almost twice as expensive. Patented drugs also cost more.
The reason for the increased price difference for patent-protected medicines is the exchange rate, said Santésuisse and Interpharma, umbrella organisations for Swiss insurers and pharmaceutical research companies, on Thursday.
At an exchange rate of CHF1.11 per euro, the 250 top-selling patented drugs were 6.9% more expensive in Switzerland in spring 2021 than in comparable foreign countries. A year ago the same medicines were only 4.5% more expensive.
The price difference for 250 patent-expired original drugs also increased, to 11.5% from 10% in 2020. However, the price difference remains by far the greatest for generics. On average, these cost 45% more in Switzerland, compared with 42% more in the previous year.
“Unfortunately the premium payers felt the increased price differences […] very directly: in Switzerland we pay over CHF200 million ($222 million) more for patent-protected medicines than in the comparable countries,” said Verena Nold, director of Santésuisse, in a statementExternal link.
Reference price system
Nold is therefore once again calling for the reference price system, which establishes a common reimbursement level or reference price for a group of interchangeable medicines. This could save the local premium payers several hundred million francs a year, she said.
“Parliament still has time this year to show its colours and stand up for the premium payers,” she said.
The price comparison was carried out for the 12th time. It compared the ex-factory prices in Switzerland with those in Belgium, Denmark, Germany, Finland, France, the United Kingdom, the Netherlands, Austria and Sweden for patented and off-patent medicines and generics.
Related Stories
Popular Stories
More
International Geneva
A Geneva-based global health foundation came close to ‘collapse’. Where were regulators?
This content was published on
Switzerland slams Israeli Doha attack as 'a clear and unacceptable violation of Qatari sovereignty and territorial integrity'.
This content was published on
The Swiss Senate does not want Switzerland to recognise the state of Palestine at present. On Tuesday it rejected an initiative by canton Geneva calling for this.
UBS economists not expecting a recession in Switzerland
This content was published on
If US tariffs remain at the current level, Swiss GDP growth could be noticeably lower than previously assumed, according to a UBS study. However, a recession is not expected.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Drug prices fall in Switzerland but generics remain expensive
This content was published on
Switzerland is narrowing the gap with other European countries when it comes to the cost of medicines. But generics are still double the price.
Costs of generic drugs and outpatient services targeted
This content was published on
The government wants to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
This content was published on
Switzerland could save millions of francs by prescribing low-priced biotech drug copies, known as biosimilars, instead of expensive biologicals.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.